49 results about "Hepatitis viral c" patented technology

This invention generally relates to a novel RNA / mRNA production and amplification method using viral RNA replicase and / or RNA-dependent RNA polymerase (RdRp) enzymes as well as the associated mRNAs thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA / mRNA sequences carrying at least an RdRp-binding site in the 5′- or 3′-end, or both. The RNA / mRNA so obtained is useful for not only producing mRNA vaccines and / or RNA-based medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase-mediated RNA / mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and / or bacteriophage RNA-dependent RNA polymerases (RdRp), particularly coronaviral and hepatitis C viral (HCV) RdRp enzymes.

Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.

The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.

To provide compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject.SOLUTION: In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, an adjuvant, or a combination thereof.SELECTED DRAWING: None

This disclosure provides a recombinant hepatitis C virus glycoprotein comprising heterodimers of E1 and E2 glycoproteins having at least 60% homology with SEQ ID No. 1, engineered furin protease cleavage sites, and hydrophilic amino acid linkers, wherein the E1 and E2 glycoproteins partially or completely lack their respective transmembrane domains. This document further provides nucleic acids encoding the recombinant hepatitis C virus glycoprotein, nanoparticle conjugates comprising the recombinant hepatitis C virus glycoprotein, and compositions comprising the recombinant hepatitis C virus glycoprotein, the nucleic acid, or the nanoparticle conjugate. Applications of the recombinant hepatitis C virus glycoprotein or compositions comprising the glycoprotein are also envisioned.

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

The invention relates to the technical field of medical examination, in particular to a rapid extraction-free hepatitis C virus detection kit and method. According to the invention, the material carrier is used for providing carrier support for reagent freeze-drying, and during use, the remelting buffer solution is used for remelting, so that the use effect before freeze-drying is achieved. The kit provided by the invention is used as a freeze-drying reagent, and solves the problem of cold-chain transportation of nucleic acid detection kits. The product simulates storage under different temperature conditions, detection results show that the product changes within 15 months, the storage period exceeds that of a control kit, and a new direction is laid for development and exploration of a later nucleic acid detection kit (pcr method). The kit disclosed by the invention lays a foundation for market occupation and long-term development by utilizing storage stability and transportation stability of the kit.

The application provides an RT-RAP primer probe set and kit for detecting blood viruses, and belongs to the technical field of molecular biology. The primer probe set comprises a primer probe set for detecting hepatitis B virus, and / or a primer probe set for detecting hepatitis C virus, and / or a primer probe set for detecting human immunodeficiency virus. The application adopts the detection means of RT-RAA and qPCR in sequence, and can simultaneously and rapidly detect hepatitis B virus, hepatitis C virus and human immunodeficiency virus in combination with the specific primer probe set, has higher sensitivity than ordinary qPCR, greatly shortens the reaction time, and has good specificity.

The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The present disclosure provides immunogenic compositions comprising one or more T-cell epitope polypeptides, or a fusion polypeptide comprising two or more T-cell epitope polypeptides. The present disclosure provides a method for inducing an immune response to hepatitis C virus in an individual, the method comprising administering to the individual an immunogenic composition of the present disclosure.

Methods of identifying virus antigens are provided. In particular the antigens induce broadly neutralizing antibodies in Hepatitis C virus infections. Compositions for inducing an immune response are identified by the methods described herein.

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

The invention discloses a label-free double-gene synchronous detection system and a label-free double-gene synchronous detection method for optical fiber-assisted enzymatic recombinase amplification, the detection system adopts two sections of conical micro optical fibers with different interference characteristics as sensing substrates, and nucleic acid primer pairs targeting hepatitis B virus (HBV) and hepatitis C virus (HCV) are respectively fixed by click chemistry; spatial separation and amplification of double-target nucleic acid are realized; amplification products are enriched in situ on the surface of the optical fiber, local refractive index changes are caused, interference spectrums are modulated, through Fourier frequency domain analysis and band-pass filtering, target signals can be separated and tracked in real time, dependence of fluorescence labeling and thermal circulation is avoided, and the detection process and the system structure are remarkably simplified. The detection system has the advantages of high sensitivity, strong specificity and compact structure, is suitable for multi-target detection scenes such as virus co-screening and early diagnosis of diseases, is expected to realize portable deployment and remote distributed application in a resource limited environment, and has good clinical conversion value and popularization prospect.

This invention generally relates to a novel composition of RNA / mRNA medicines as well as vaccines produced by using replicase- and / or RNA-dependent RNA polymerase (RdRp)-mediated RNA cycling reaction (RCR). The present invention is useful for developing a variety of self-amplifying RNA / mRNA (samRNA) medicines and vaccines containing at least a replicase / RdRp-binding site in the 5′- or 3′-end, or both, of any desired RNA molecule, including but not limited to antisense RNA (aRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA) / miRNA precursor, long non-coding RNA (lnRNA) and mRNA. These RNA molecules can be either in single-stranded or in double-stranded, or mixed, conformation. The samRNA so obtained is useful not only for producing RNA-based vaccines and / or medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under a proper in-vitro or in-cell translation condition. The replicase / RdRp-binding sites used in samRNA are derived or modified from coronaviral (e.g. COVID-19) and / or hepatitis C viral (HCV) RNA-dependent RNA polymerases (RdRp) in either single-stranded or double-stranded compositions.

The present application relates to the technical field of biomedical detection, and particularly relates to a kit for detecting treponema pallidum and hepatitis C virus antibodies in oral mucosa exudate based on colloidal selenium method, and a test strip for detecting treponema pallidum and hepatitis C virus antibodies in oral mucosa exudate based on colloidal selenium method. The test strip comprises a base plate, a sample pad, a colloidal selenium pad, a nitrocellulose membrane and a water absorption pad. The sample pad, the colloidal selenium pad, the nitrocellulose membrane and the water absorption pad are sequentially and adjacently pasted on the base plate in the chromatographic direction. The nitrocellulose membrane is provided with a quality control line and two detection lines. The quality control line is coated with sheep anti-mouse IgG. The two detection lines are respectively coated with TP recombinant antigen 2 and HCV recombinant antigen 2. The colloidal selenium pad is coated with colloidal selenium-labeled SPA. The kit disclosed by the present application has the advantages of convenient use and simple operation. The detection sample is oral mucosa exudate, and the non-invasive sampling avoids cross infection caused by blood sampling and other use modes.

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatopepatitis (NASH).

Provided herein are compositions and methods that allow for controlled interaction between a target protein and a polypeptide to which a binding protein is fused. Compositions and methods utilize a target protein that binds to the hepatitis C virus protease inhibitor glaprevir to form a complex, and a Tn3 binding protein that specifically binds to the complex. The target protein is or is derived from a viral protease, such as an HCV NS3 / 4A protease.

The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising at least parts of the HCV core protein, and HCV E1 and HCV E2 protein of a specific HCV strain, as well as VSV-G protein. The proteins may be assembled in rVSV-HCV particles. This has been identified to induce particularly advantageous broadly neutralizing antibodies. The invention further provides nucleic acids encoding said HCV proteins and VSV proteins but not encoding VSV-G protein. Vaccines comprising the particles, compositions or nucleic acids are disclosed as useful, in particular, for prophylactic vaccination against HCV. Methods of producing the rVSV-HCV particles or compositions of the invention and the produced particles and compositions are also subject-matter of the invention.

The present application relates to the technical field of biological detection, in particular to a kit for detecting hepatitis C virus core protein binding protein 6 and application thereof. The present application provides an HCBP6 enzyme-linked immunoassay kit, which is obtained by antibody screening and reagent optimization. The kit is used for detecting the content of HCBP6 in human serum, and has the advantages of high detection sensitivity, wide linear range, good precision, high accuracy, simple and rapid operation, wide application site, relatively low detection cost, and the like, and is conducive to guiding the diagnosis and treatment of fatty liver in clinic.

The present application relates to a circRNA vaccine for anti-infectious hematopoietic necrosis virus, the circRNA vaccine is a covalently closed circular structure, comprising an internal ribosome entry site, a G protein sequence of the infectious hematopoietic necrosis virus, and a Kozak sequence located between the internal ribosome entry site and the G protein sequence of the infectious hematopoietic necrosis virus;The circRNA vaccine comprises a cyclization connection sequence formed by a fish tRNA Leu I type intron self-splicing;The internal ribosome entry site is one or more of the following: coxsackievirus 3 IRES, infectious pancreatic necrosis virus IRES, encephalomyocarditis virus IRES, Ythdc2 IRES, and hepatitis C virus IRES;The amino acid sequence of the G protein of the infectious hematopoietic necrosis virus has at least 90% sequence identity with the amino acid sequence encoded by SEQ ID NO. 1.

A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:

The present invention relates to monoclonal antibodies to the HCV core lipid binding domain. The present invention provides monoclonal antibodies for detecting Hepatitis C Virus (HCV) antigens. The antibodies specifically immunoreact with at least one epitope of the lipid binding domain of amino acid residues 134-171 of the HCV core antigen. Further provided are immunoassay methods for detecting HCV infection using the antibodies, kits comprising the antibodies, and compositions.

Provided are: a method for determining the onset risk of hepatocellular carcinoma in a hepatitis C virus-infected subject having achieved virological response, the method being characterized by measuring binding between a Mac-2 binding protein and at least two types of lectin selected from the group consisting of TJA-I, AAL, ECA, LCA, AOL, PSA, SNA, GSL-II, NPA, ConA, ACG, BPL, TJA-II, ABA, UDA, DSA, and WFA; and a method for screening for a compound that reduces said risk.

Disclosed are bifunctional compounds (degraders) that target hepatitis C virus (HCV) NS3 / 4A for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat HCV infection and HCV-associated diseases or disorders.

The present invention relates to nucleoside compound for the treatment of Hepatitis C viral infections including compound of formula I, pharmaceutical composition comprising these compound.

This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis C virus (HCV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the 5′ untranslated region of HCV and are configured to provide substantially equivalent quantification of different genotypes and variants of HCV.

Disclosed are a trimerization regulatory element, a method for constructing same, and use thereof. In addition to a protein A and a protein B that are obtained by splitting the hepatitis C virus protease NS3a, the trimerization regulatory element comprises a protein C. The trimerization of the trimerization regulatory element can be mediated by means of a targeting drug specific to the protease NS3a (grazoprevir / danoprevir). The trimerization regulatory element provided by the present invention has an excellent small-molecule-mediated trimerization effect, and a drug approved by the National Medical Products Administration is used. The protein used does not exist in the human body; therefore, the protein can result in better biological orthogonality. Moreover, the protein can be used as a clinically effective drug regulatory switch, effectively avoiding problems such as serious cytotoxicity and off-target effects.